Tanespimycin
- Generic Name
- Tanespimycin
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C31H43N3O8
- CAS Number
- 75747-14-7
- Unique Ingredient Identifier
- 4GY0AVT3L4
- Background
Tanespimycin, manufactured by Conforma Therapeutics is under development as a small molecule inhibitor of heat shock protein 90 (HSP90). It is developed for the treatment of several types of cancer, solid tumors or chronic myelogenous leukemia.
- Indication
Investigated for use/treatment in leukemia (myeloid) and solid tumors.
- Associated Conditions
- -
- Associated Therapies
- -
17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Advanced Epithelial Cancer, Malignant Lymphoma, or Sarcoma
Phase 1
Completed
- Conditions
- AIDS-related Peripheral/Systemic LymphomaAIDS-related Primary CNS LymphomaAnaplastic Large Cell LymphomaAngioimmunoblastic T-cell LymphomaChondrosarcomaExtranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid TissueIntraocular LymphomaMetastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal TumorMetastatic OsteosarcomaNodal Marginal Zone B-cell Lymphoma
- Interventions
- Drug: tanespimycinOther: pharmacological study
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-02-07
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 60
- Registration Number
- NCT00004241
- Locations
- 🇺🇸
University of Pittsburgh, Pittsburgh, Pennsylvania, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath